AAAAAA
Results:
1-13
|
Results: 13
Authors:
Galanis, E
Bateman, A
Johnson, K
Diaz, RM
James, CD
Vile, R
Russell, SJ
Citation: E. Galanis et al., Use of viral fusogenic membrane glycoproteins as novel therapeutic transgenes in gliomas, HUM GENE TH, 12(7), 2001, pp. 811-821
Authors:
Galanis, E
Vile, R
Russell, SJ
Citation: E. Galanis et al., Delivery systems intended for in vivo gene therapy of cancer: targeting and replication competent viral vectors, CR R ONC H, 38(3), 2001, pp. 177-192
Authors:
Emiliusen, L
Gough, M
Bateman, A
Ahmed, A
Voellmy, R
Chester, J
Diaz, RM
Harrington, K
Vile, R
Citation: L. Emiliusen et al., A transcriptional feedback loop for tissue-specific expression of highly cytotoxic genes which incorporates an immunostimulatory component, GENE THER, 8(13), 2001, pp. 987-998
Authors:
Todryk, S
Melcher, A
Bottley, G
Gough, M
Vile, R
Citation: S. Todryk et al., Cell death associated with genetic prodrug activation therapy of colorectal cancer, CANCER LETT, 174(1), 2001, pp. 25-33
Authors:
Grote, D
Russell, SJ
Cornu, TI
Cattaneo, R
Vile, R
Poland, GA
Fielding, AK
Citation: D. Grote et al., Live attenuated measles virus induces regression of human lymphoma xenografts in immunodeficient mice, BLOOD, 97(12), 2001, pp. 3746-3754
Authors:
Lowenstein, P
Stone, D
David, A
Melcher, A
Vile, R
Thomas, C
Bataille, D
Castro, M
Citation: P. Lowenstein et al., Therapeutic applications of viral vectors, GENETICALLY ENGINEERED VIRUSES, 2001, pp. 215-254
Authors:
Vile, R
Citation: R. Vile, Cancer gene therapy - new approaches to tumour cell killing, J GENE MED, 2(2), 2000, pp. 141-143
Authors:
Ali, SA
McLean, CS
Boursnell, MEG
Martin, G
Holmes, CL
Reeder, S
Entwisle, C
Blakeley, DM
Shields, JG
Todryk, S
Vile, R
Robins, RA
Rees, RC
Citation: Sa. Ali et al., Preclinical evaluation of "whole" cell vaccines for prophylaxis and therapy using a disabled infectious single cycle-herpes simplex virus vector to transduce cytokine genes, CANCER RES, 60(6), 2000, pp. 1663-1670
Authors:
Peng, KW
Vile, R
Citation: Kw. Peng et R. Vile, Vector development for cancer gene therapy, TUMOR TARG, 4(1), 1999, pp. 3-11
Authors:
Melcher, A
Murphy, S
Vile, R
Citation: A. Melcher et al., Heat shock protein expression in target cells infected with low levels of replication-competent virus contributes to the immunogenicity of adenoviralvectors, HUM GENE TH, 10(9), 1999, pp. 1431-1442
Authors:
Todryk, S
McLean, C
Ali, S
Entwistle, C
Boursnell, M
Rees, R
Vile, R
Citation: S. Todryk et al., Disabled infectious single-cycle herpes simplex virus as an oncolytic vector for immunotherapy of colorectal cancer, HUM GENE TH, 10(17), 1999, pp. 2757-2768
Anti-tumour activity against B16-F10 melanoma with a GM-CSF secreting allogeneic tumour cell vaccine
Authors:
Kayaga, J
Souberbielle, BE
Sheikh, N
Morrow, WJW
Scott-Taylor, T
Vile, R
Dalgleish, AG
Citation: J. Kayaga et al., Anti-tumour activity against B16-F10 melanoma with a GM-CSF secreting allogeneic tumour cell vaccine, GENE THER, 6(8), 1999, pp. 1475-1481
Authors:
Melcher, A
Gough, M
Todryk, S
Vile, R
Citation: A. Melcher et al., Apoptosis or necrosis for tumor immunotherapy: what's in a name?, J MOL MED-J, 77(12), 1999, pp. 824-833
Risultati:
1-13
|